Saturday, 20 October 2018
Neoadjuvant treatments by Christian Blank
Why treating early stage patients?
Early stage patients have all the favourable disease outcomes that we know from Stage 4
Why treating neoadjuvant
1. we know whether therapy was effective
2. we can reduce tumour burden very fast- easier surgery
3. we can use pathological response as an outcome parameter
4. in case of checkpoint- inhibitors induces a broader and deeper expansion of T-cell clones
5. easier baseline biomarker identification
pure neo-adjuvant with 12 weeks: still relapses, so not the way to go
(Georgina Long's work)
neo-adjuvant seems better than adjuvant- and patients do not relapse
Problem: very high toxicity
and PD1 monotherapy neo-adjuvant considerably lower response rate when compared to Ipi plus Nivo
also longer treatment with PD1 not successful
so which way to go?
OPACIN- neo trial- late breaker on Monday
lower ipi dose in combination
altered admin scheme
'test your favourite combinations in neo-adjuvant' NAHHHH
and you will chose the *most promising* option, so time for research!
Fake News and Pseudoscience are dangerous for patients. So very pleased and incredibly proud to see Gilly's session covered on the ...
Why treating early stage patients? Early stage patients have all the favourable disease outcomes that we know from Stage 4 cancer immu...
Also this year- updates from ESMO! The program is available online here
Rotterdam criteria Again- tumorload below 0.1 equals no tumour load in the sentinel node in Stage 3A- check out the Rotterdam criteria ...